Mabswitch develops regulatable antibodies using proprietary UNASMA™ technology to control binding affinity under physiological conditions. This platform enables next-generation immunotherapeutics, diagnostics, and immunoaffinity reagents with improved patient outcomes and functionality. The technology addresses limitations of irreversible antibody binding in therapeutic, diagnostic, and bioprocessing applications.
Funding
$50K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current antibody therapies and diagnostics often suffer from irreversible binding to their targets, which can lead to adverse events in therapeutic settings, prevent antibody regeneration in diagnostics, and hinder target macromolecule elution under physiological conditions in bioprocessing. The inability to regulate antibody affinity limits the safety, efficacy, and reusability of these critical tools.
Solution
MabSwitch is developing ON/OFF control switches for antibodies using its proprietary Universal Allosteric linker and Switch Module for Antibodies (UNASMA™) technology. This technology enables the regulation of antibody affinity for its target under physiological conditions, addressing the challenges associated with irreversible binding. By controlling antibody affinity, MabSwitch aims to improve patient outcomes in immunotherapeutics, enhance antibody regeneration in diagnostics, and facilitate gentle elution of target macromolecules in bioprocessing applications. The technology has the potential to improve the safety, efficacy, and versatility of antibody-based products across various applications.
Target Audience
The primary target audience includes biopharmaceutical companies developing antibody-based therapeutics and diagnostics, as well as researchers and manufacturers utilizing antibodies for immunoaffinity purification and bioprocessing.
Features
- Universal Allosteric Linker technology for modulating antibody affinity.
- Switch Module for Antibodies (UNASMA™) enabling ON/OFF control.
- Regulation of antibody binding under physiological conditions.
- Potential applications in immunotherapeutics, diagnostics, and immunoaffinity purification.